Skip to search formSkip to main contentSkip to account menu

PF 03814735

Known as: Aurora Kinase Inhibitor PF-03814735, PF-03814735, PF03814735 
An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Thyroid cancer (TC) is a very common malignancy worldwide. Chief among the innovative molecular drug targets for TC are… 
2019
2019
Review
2015
Review
2015
Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers, making them an ideal… 
2013
2013
Pulmonary carcinoids comprise a well-differentiated subset of neuroendocrine tumors usually associated with a favorable prognosis… 
Highly Cited
2012
Highly Cited
2012
PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment… 
Highly Cited
2010
Highly Cited
2010
The Aurora family of highly related serine/threonine kinases plays a key role in the regulation of mitosis. Aurora1 and Aurora2… 
2008
2008
2517 Background: Aurora kinases are a family of kinases that play a crucial role in regulating segregation of chromosomes and… 
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…